Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL30496141 | 1.00 | HTT (0.57) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL30078131 | 0.97 | HTT (0.59) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL1583292 | 0.97 | HTT (0.59) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL2930759 | 0.95 | HTT (0.58) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Nitric Acid SCHEMBL3635730 | 0.93 | CYP3A4 (0.61) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Sulfuric Acid SCHEMBL21799346 | 0.92 | ALDH1A1 (0.57) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Nitric Acid SCHEMBL3858360 | 0.88 | GRIN2D (0.60) | HTTSMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL4107531 | 0.86 | HTT (0.54) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL11876436 | 0.85 | GRIN2D (0.63) | HTTSMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL5527561 | 0.83 | HTT (0.65) | HTTSMN1; SMN2ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496627-B | FRP composite material and preparation method and application thereof | 南京斯贝尔复合材料仪征有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118496627-A | FRP composite material and preparation method and application thereof | 南京斯贝尔复合材料仪征有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-114790154-B | Preparation method of antitumor drug imatinib intermediate (2-methyl-5-nitrophenyl) guanidine nitrate | 福建南方制药股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-114790154-A | Preparation method of antineoplastic drug imatinib intermediate- (2-methyl-5-nitrophenyl) guanidine nitrate | 福建南方制药股份有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-112827368-A | Anti-pollution reverse osmosis membrane and preparation method thereof | 中化(宁波)润沃膜科技有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| EP-3333162-A1 | METOD FOR PREPARING N-(2-METHYL-5-NITROPHENYL)-4-(PYRIDIN-3-YL)PYRIMIDIN-2-AMINE | Silesian Catalysts sp. z o.o. (PL) | 2018-06-13 | — | — | EP | claimed |
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | claimed |
| CN-102911157-B | (E)-3-[2-bromo-5-(3-substituted propoxy)]phenyl-N-{4-methyl-3-[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl acrylamide compound | UNIV SHENYANG PHARMACEUTICAL | 2014-04-02 | — | — | CN | claimed |
| EP-1833815-B1 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INST FARMACEUTYCZNY (PL) | 2010-09-15 | — | — | EP | claimed |
| US-7674901-B2 | Process for preparation of imatinib base | INSTYTUT FARMACEUTYCZNY (PL) | 2010-03-09 | — | — | US | claimed |
| US-20080194819-A1 | Process For Preparation of Imatinib Base | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-14 | — | — | US | claimed |
| EP-1833815-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2007-09-19 | — | — | EP | claimed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | claimed |
| WO-2004108699-A1 | PROCESS FOR THE PREPARATION OF THE ANTI-CANCER DRUG IMATINIB AND ITS ANALOGUES | NATCO PHARMA LIMITED (IN) | 2004-12-16 | — | — | WO | claimed |
| CN-118496627-B | FRP composite material and preparation method and application thereof | 南京斯贝尔复合材料仪征有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118496627-A | FRP composite material and preparation method and application thereof | 南京斯贝尔复合材料仪征有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| CN-1077713-A | Pyrimidine derivatives and preparation method thereof | CIBA GEIGY AG (CH) | 1993-10-27 | — | — | CN | disclosed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194819-A1 | Process For Preparation of Imatinib Base | ABL1, ABL2, JAK2 | HTT 2724/4885SMN1; SMN2 1248/4885ALDH1A1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.